Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $240,000.00

Wall Street brokerages expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report sales of $240,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $300,000.00. Abeona Therapeutics posted sales of $260,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 7.7%. The company is scheduled to announce its next quarterly earnings results on Friday, March 30th.

On average, analysts expect that Abeona Therapeutics will report full-year sales of $240,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $900,000.00. For the next financial year, analysts anticipate that the firm will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 23.95% and a negative net margin of 2,439.73%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million.

Several equities research analysts recently commented on the company. ValuEngine cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Maxim Group set a $17.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 16th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, November 22nd. Zacks Investment Research lowered shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Finally, Jefferies Group restated a “buy” rating and issued a $28.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, November 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Abeona Therapeutics has a consensus rating of “Buy” and an average target price of $26.10.

Shares of Abeona Therapeutics (ABEO) opened at $15.30 on Tuesday. Abeona Therapeutics has a twelve month low of $4.05 and a twelve month high of $22.75.

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Abeona Therapeutics by 11.2% during the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after buying an additional 108,730 shares during the last quarter. State Street Corp acquired a new position in shares of Abeona Therapeutics during the second quarter valued at about $1,900,000. Northern Trust Corp raised its position in shares of Abeona Therapeutics by 406.3% during the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after buying an additional 206,775 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Abeona Therapeutics during the third quarter valued at about $3,527,000. Finally, Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 2.4% during the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the last quarter. 41.95% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://weekherald.com/2017/12/14/zacks-analysts-anticipate-abeona-therapeutics-inc-abeo-will-post-quarterly-sales-of-240000-00.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply